Country: Unjoni Ewropea
Lingwa: Ingliż
Sors: EMA (European Medicines Agency)
empagliflozin
Boehringer Ingelheim International GmbH
A10BK03
empagliflozin
Drugs used in diabetes
Diabetes Mellitus, Type 2; Heart Failure; Renal Insufficiency, Chronic
Type 2 diabetes mellitusJardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered in addition to other medicinal products for the treatment of diabetesFor study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1. of the annex.Heart failureJardiance is indicated in adults for the treatment of symptomatic chronic heart failure. Chronic kidney diseaseJardiance is indicated in adults for the treatment of chronic kidney disease.
Revision: 28
Authorised
2014-05-22
50 B. PACKAGE LEAFLET 51 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT JARDIANCE 10 MG FILM-COATED TABLETS JARDIANCE 25 MG FILM-COATED TABLETS empagliflozin READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Jardiance is and what it is used for 2. What you need to know before you take Jardiance 3. How to take Jardiance 4. Possible side effects 5. How to store Jardiance 6. Contents of the pack and other information 1. WHAT JARDIANCE IS AND WHAT IT IS USED FOR WHAT JARDIANCE IS Jardiance contains the active substance empagliflozin. Jardiance is a member of a group of medicines called sodium glucose co-transporter-2 (SGLT2) inhibitors. WHAT JARDIANCE IS USED FOR TYPE 2 DIABETES MELLITUS Jardiance is used to treat type 2 diabetes in adults and children aged 10 years and older that cannot be controlled by diet and exercise alone. Jardiance can be used without other medicines in patients who cannot take metformin (another diabetes medicine). Jardiance can also be used with other medicines for the treatment of diabetes. These may be medicines taken by mouth or given by injection such as insulin. Jardiance works by blocking the SGLT2 protein in your kidneys. This causes blood sugar (glucose) to be removed in your urine. Thereby Jardiance lowers the amount of sugar in your blood. This medicine can also help prevent heart disease in patients with type 2 diabetes mellitus. It is important that you continue with your diet and exercise plan as told by your doctor, pharmacist or nurse. H Aqra d-dokument sħiħ
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Jardiance 10 mg film-coated tablets Jardiance 25 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Jardiance 10 mg film-coated tablets Each tablet contains 10 mg empagliflozin. _Excipients with known effect_ Each tablet contains lactose monohydrate equivalent to 154.3 mg lactose anhydrous. Jardiance 25 mg film-coated tablets Each tablet contains 25 mg empagliflozin. _Excipients with known effect_ Each tablet contains lactose monohydrate equivalent to 107.4 mg lactose anhydrous. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet). Jardiance 10 mg film-coated tablets Round, pale yellow, biconvex, bevel-edged film-coated tablet debossed with “S10” on one side and the Boehringer Ingelheim logo on the other (tablet diameter: 9.1 mm). Jardiance 25 mg film-coated tablets Oval, pale yellow, biconvex film-coated tablet debossed with “S25” on one side and the Boehringer Ingelheim logo on the other (tablet length: 11.1 mm, tablet width: 5.6 mm). 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Type 2 diabetes mellitus Jardiance is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise - as monotherapy when metformin is considered inappropriate due to intolerance - in addition to other medicinal products for the treatment of diabetes For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1. 3 Heart failure Jardiance is indicated in adults for the treatment of symptomatic chronic heart failure. Chronic kidney disease Jardiance is indicated in adults for the treatment of chronic kidney disease. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Type 2 diabetes mellitus The recommended starting dose is 10 mg empagliflozin once daily for monothe Aqra d-dokument sħiħ